Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04863014
Recruitment Status : Terminated (Sponsor Decision)
First Posted : April 28, 2021
Last Update Posted : March 22, 2023
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The primary objective of the study is to determine the proportion of patients with elevated triglycerides (TG), without familial chylomicronemia syndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL), and a history of hypertriglyceridemia (HTG)-associated acute pancreatitis (AP) who experience a recurrent episode of AP after treatment with evinacumab versus placebo.

The secondary objectives of the study are:

  • To determine the change in the standard lipid profile after therapy with evinacumab versus placebo
  • To determine the changes in specialty lipoprotein parameters (ApoC3, ApoB48, ApoB100, and nuclear magnetic resonance [NMR] lipid profile) after therapy with evinacumab versus placebo
  • To measure the number of AP episodes per patient
  • To assess the safety and tolerability of evinacumab
  • To assess the potential immunogenicity of evinacumab
  • To assess the concentrations of total evinacumab and total angiopoietin-like 3 (ANGPTL3)

Condition or disease Intervention/treatment Phase
Hypertriglyceridemia Drug: evinacumab Other: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
Actual Study Start Date : July 12, 2021
Actual Primary Completion Date : February 15, 2023
Actual Study Completion Date : February 15, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis
Drug Information available for: Evinacumab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: evinacumab
Randomized 1:1
 Drug: evinacumab
Intravenous infusion every 4 weeks (Q4W)
Other Names:
  • REGN1500
  • Evkeeza™
Placebo Comparator: Placebo
Randomized 1:1
 Other: Placebo
Intravenous infusion Q4W


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Proportion of patients with at least 1 positively adjudicated acute pancreatitis (AP) episode [ Time Frame: Up to 52 weeks ]

Secondary Outcome Measures :
  1. Percent change in ApoC3 [ Time Frame: Baseline to week 52 ]
  2. Percent change in fasting triglycerides (TGs) [ Time Frame: Baseline to week 52 ]
  3. Percent change in total cholesterol (TC) [ Time Frame: Baseline to week 52 ]
  4. Percent change in non-high-density lipoprotein cholesterol (non-HDL-C) [ Time Frame: Baseline to week 52 ]
  5. Percent change in ApoB48 [ Time Frame: Baseline to week 52 ]
  6. Percent change in ApoB100 levels [ Time Frame: Baseline to week 52 ]
  7. Percent change in nuclear magnetic resonance (NMR)-determined particle size and number [ Time Frame: Baseline to week 52 ]
  8. Number of independently adjudicated episodes of AP per patient [ Time Frame: Up to 52 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Adults without FCS due to LPL loss of function mutations
  2. Documented history of 1 HTG-associated AP episode within 24 months of screening
  3. Fasting serum TG value >880 mg/dL (10 mmol/L) or >500 mg/dL (5.6mmol/L) determined during the screening period as described in the protocol
  4. Stable dose of lipid-lowering therapy (≥8 weeks) and willingness to maintain a stable regimen throughout the study
  5. Body mass index ≥18.0 and ≤45.0 kg/m2
  6. Compliance with a stable diet and exercise regimen at screening and willingness to continue the diet through the end of the study

Key Exclusion Criteria:

  1. Hospitalization for AP within 4 weeks of screening
  2. Known genetic FCS defined as homozygous or compound heterozygous LoF mutations in LPL as defined in the protocol
  3. Symptomatic gallstone disease within 6 months prior to screening as defined in the protocol
  4. Use of any medication or nutraceutical known to alter serum lipids which has not been part of a stable therapeutic regimen for at least 8 weeks, and there are no plans to change the regimen during the study
  5. Presence of any clinically significant, uncontrolled endocrine disease known to influence serum lipids as defined in the protocol
  6. Has received a COVID-19 vaccination within 1-week of planned start medication or for which the planned COVID-19 vaccination would not be completed 1-week prior to start of the study

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04863014


Locations
Show Show 39 study locations
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04863014    
Other Study ID Numbers: R1500-HTG-20118
2021-000437-13 ( EudraCT Number )
First Posted: April 28, 2021    Key Record Dates
Last Update Posted: March 22, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access Criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Regeneron Pharmaceuticals:
Severe Hypertriglyceridemia (HTG)
Recurrent Acute Pancreatitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatitis
Hypertriglyceridemia
Pancreatic Diseases
Digestive System Diseases
 Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases